Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (DART)
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This research study is led by Dr. John McCann.
Contact: Katie Colbeck, 413-794-9875
June 09, 2017
Cancer - Brain,
Cancer - Breast,
Cancer - Colon,
Cancer - Esophogus,
Cancer - Kidney,
Cancer - Leukemia,
Cancer - Lung,
Cancer - Lymphoma,
Cancer - Melanoma,
Cancer - Multiple Myeloma,
Cancer - Pancreatic,
Cancer - Prostate
- D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Baystate Franklin Medical Center, 164 High Street, Greenfield, MA
Patients must have histologically confirmed rare cancer and/or cancer of unknown primary, that did not have a match to a molecularly-guided therapy on EAY131 “NCI-MATCH” protocol or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations per EAY131, “NCI-MATCH”.
Interventional (Clinical Trial), Non-Randomized